The Molecular Tumour Board (MTB) is an interdisciplinary tumour conference at which medical and scientific specialists from various departments discuss complicated cases of cancer. The results of molecular pathological diagnostics are discussed in light of the latest scientific findings. A recommendation is then made for a precisely tailored treatment plan, further diagnostics or participation in a study. MTBs are playing an increasingly important role in the implementation of precision oncology (1) (2).
The MTB is conducted within the Central German Cancer Centre in cooperation with the University Tumour Centre (UTC) Jena.
Time:
- every 14 days (odd calendar weeks), Wednesdays at 3 p.m.
- Registration deadline: Thursday of the preceding week, 2 p.m.
- Registration is carried out by the attending physicians.
Beteiligte:
- Der/die Behandelnde (jeweiliges Organzentrum),
- Onkologie
- Pathologie/Molekularpathologie,
- Humangenetik,
- Molekularbiologie,
- Bioinformatik,
- Phase I Studienteam (ECTU),
- weitere je nach Bedarf (Chirurgie, Radiologie)
Literatur:
1. Yates LR, Seoane J, Le Tourneau C, et al: The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Ann Oncol 2018;29:30-35
2. Westphalen BC, Bokemeyer C, Buttner R, et al: Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. Eur J Cancer 2020;135:1-7
